Ibex Investors’s ChemoCentryx, Inc. CCXI Stock Holding History

Ibex Investors’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-20,974	Closed	-$285K	–	257
2018 Q1	$285K	Buy	+20,974	New	+$216K	0.23%	165

Other funds holding CCXI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ibex Investors's CCXI Position: Q2 2018 in Review

Ibex Investors sold out of ChemoCentryx, Inc. (CCXI) in Q2 2018, closing a stake of 20,974 shares — an estimated $285K sold.

Ibex Investors first reported a position in CCXI in Q1 2018 and held it in 1 quarter. The position peaked at $285K in Q1 2018. 115 funds tracked by Wall St. Rank hold CCXI as of Q2 2018.

Ibex Investors reported no remaining ChemoCentryx, Inc. position as of Q2 2018 after selling out during the quarter.
Ibex Investors sold 20,974 ChemoCentryx, Inc. shares in Q2 2018, an estimated $285K.
Ibex Investors first reported a position in ChemoCentryx, Inc. in Q1 2018 and held it in 1 quarter.
Ibex Investors's ChemoCentryx, Inc. position peaked at $285K in Q1 2018.
115 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2018.

Based on Ibex Investors's 13F filing for Q2 2018, filed 14 Aug 2018.